Loading…
www.24hreup.biz, a Germany-based online retailer, was cited for unlawfully selling unapproved and misbranded semaglutide drug products to U.S. consumers in violation of the Federal Food, Drug, and Cosmetic Act (sections 301(a), 301(d), 301(k), 503(b), and 505(a)). The company's products circumvented FDA regulatory oversight and posed inherent safety risks, as unapproved drugs may be contaminated, counterfeit, contain inconsistent active ingredient amounts, or include entirely different ingredients. The FDA requested immediate cessation of all unapproved and misbranded drug sales to U.S. consumers to protect public health.